Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Carboxymethylcellulose Sodium 0.5%, Carboxymethylcellulose 0.5%
Carboxymethylcellulose and Glycerin · 2 trials · 2 indications
Percentage of Subjects Tabulated by Changes in Line Number at Day 90 from Baseline; Visual Acuity measured by LogMar reported as Snellen equivalents. Better: an increase of 2 lines or more in at least one eye; No Change: a change less than +/- 2 lines in both eyes; Worse: a decrease of 2 lines or more in at least one eye.
| Arm | Type | Description |
|---|---|---|
| Carboxymethylcellulose sodium and Glycerin | EXPERIMENTAL | Carboxymethylcellulose sodium and Glycerin based rewetting drop |
| Carboxymethylcellulose sodium | ACTIVE_COMPARATOR | Carboxymethylcellulose sodium based rewetting drop |
| Name | Type | Description |
|---|---|---|
| Carboxymethylcellulose sodium and Glycerin | DEVICE | Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses. |
| Carboxymethylcellulose sodium | DEVICE | Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses. |
Inclusion Criteria: * Adapted contact lens wearer Exclusion Criteria: * Monovision lens wearer, ocular or systemic disease, pregnant or planning to become pregnant
Carboxymethylcellulose and glycerin is an investigational lubricant eye drop being studied for dry eye and for rewetting contact lenses in people with ametropia. It is designed as a topical ophthalmic drop. Both studied uses are in Phase 2 clinical development, and the product is not described as approved for marketing.
AbbVie Inc. (ticker ABBV) is the developer of carboxymethylcellulose and glycerin. The company has sponsored the clinical program evaluating this lubricant eye drop formulation in ophthalmology indications, including dry eye and contact lens rewetting. No other developer or partner is identified for this asset.
Carboxymethylcellulose and glycerin is in Phase 2 clinical development. Two Phase 2 studies have been completed, one in dry eye and one in ametropia, and no active trials are currently listed. The asset remains investigational and has not been described as FDA approved.
Two completed Phase 2 trials have evaluated carboxymethylcellulose and glycerin. NCT00691197 studied safety and acceptability of a rewetting drop with contact lens wear in 246 participants with ametropia. NCT00243711 was a multi-center randomized study of an investigational lubricant eye drop in 286 participants with dry eye. Both were conducted in the United States.
Yes. Carboxymethylcellulose and glycerin is also known as carboxymethylcellulose sodium and glycerin, carboxymethylcellulose sodium 0.5%, and carboxymethylcellulose 0.5%. These names refer to the same investigational ophthalmic lubricant formulation developed by AbbVie Inc. for dry eye and contact lens rewetting.
The Phase 2 program for carboxymethylcellulose and glycerin used randomized, double-blind, active-controlled designs. NCT00243711 enrolled 286 participants with dry eye, and NCT00691197 enrolled 246 contact lens wearers with ametropia, including healthy volunteers. Both studies required participants to be at least 18 years old and enrolled all sexes.